 Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily on May 1 by the Securities and Exchange Commission in a halt that was meant to expire at 11.59 p.m. on May 15. The halt came because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19, the SEC said. Moleculins stock was halted along with CNS and WPD Pharmaceuticals Inc. , because of questions relating to a drug candidate called WP1122. CNS was working with WPD to develop the drug; WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions. 